Kura Oncology Inc

NASDAQ KURA

Data sourced from

and

Download Data

Kura Oncology Inc EBIT Ratio 1 year YoY Change (%) for the quarter ending September 19, 2024

Kura Oncology Inc EBIT Ratio 1 year YoY Change (%) is NA for the quarter ending September 19, 2024. EBIT Ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

NASDAQ: KURA

Kura Oncology Inc

CEO	Dr. Troy Edward Wilson J.D., Ph.D.
IPO Date	Sept. 22, 2015
Location	United States
Headquarters	12730 High Bluff Drive, San Diego, CA, United States, 92130
Employees	142
Sector	Healthcare
Industry	Biotechnology

Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Key trends